Immunogenicity of Anti-TNF Biologic Therapies for Rheumatoid Arthritis

Overview

Journal Nat Rev Rheumatol

Specialty Rheumatology

Date 2013 Feb 13

PMID 23399692

Citations 161

Authors

Pauline A van Schouwenburg

Theo Rispens

Gerrit Jan Wolbink

Affiliations

Soon will be listed here.

Abstract

Currently, five anti-TNF biologic agents are approved for the treatment of rheumatoid arthritis (RA): adalimumab, infliximab, etanercept, golimumab and certolizumab pegol. Formation of anti-drug antibodies (ADA) has been associated with all five agents. In the case of adalimumab and infliximab, immunogenicity is strongly linked to subtherapeutic serum drug levels and a lack of clinical response, but for the other three agents, data on immunogenicity are scarce, suggesting that further research would be valuable. Low ADA levels might not influence the efficacy of anti-TNF therapy, whereas high ADA levels impair treatment efficacy by considerably reducing unbound drug levels. Immunogenicity is not only an issue in patients treated with anti-TNF biologic agents; the immunogenicity of other therapeutic proteins, such as factor VIII and interferons, is well known and has been investigated for many years. The results of such studies suggest that investigations to determine the optimal treatment regimen (drug dosing, treatment schedule and co-medication) required to minimize the likelihood of ADA formation might be an effective and practical way to deal with the immunogenicity of anti-TNF biologic agents for RA.

Citing Articles

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.

2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb....

Tounekti O, Prior S, Wassmer S, Xu J, Wong A, Fang X Bioanalysis. 2025; 17(3):105-149.

PMID: 39862111 PMC: 11863570. DOI: 10.1080/17576180.2024.2439229.

Detection of antibodies to infliximab in routine care: a 4-year French retrospective study.

Bertin D, Aghzadi J, Balandraud N, Roman C, Serrero M, Desplat-Jego S Clin Exp Immunol. 2024; 219(1).

PMID: 39714327 PMC: 11747995. DOI: 10.1093/cei/uxae122.

Immunogenicity of adalimumab reference product and adalimumab-adbm in patients with rheumatoid arthritis, Crohn's disease and chronic plaque psoriasis: a pooled analysis of the VOLTAIRE trials.

Strand V, McCabe D, Bender S BMJ Open. 2024; 14(11):e081687.

PMID: 39551590 PMC: 11574400. DOI: 10.1136/bmjopen-2023-081687.

Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays.

Vroemen W, Agata S, van Beers J, Damoiseaux J Antibodies (Basel). 2024; 13(3).

PMID: 39311378 PMC: 11417797. DOI: 10.3390/antib13030073.

References

Chatenoud L, Jonker M, Villemain F, Goldstein G, Bach J . The human immune response to the OKT3 monoclonal antibody is oligoclonal. Science. 1986; 232(4756):1406-8. DOI: 10.1126/science.3086976. View

Lavigne-Lissalde G, Schved J, Granier C, Villard S . Anti-factor VIII antibodies: a 2005 update. Thromb Haemost. 2005; 94(4):760-9. DOI: 10.1160/TH05-02-0118. View

Carter P . Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2002; 1(2):118-29. DOI: 10.1038/35101072. View

Locatelli F, Del Vecchio L, Pozzoni P . Pure red-cell aplasia "epidemic"--mystery completely revealed?. Perit Dial Int. 2007; 27 Suppl 2:S303-7. View

Jaffers G, Fuller T, Cosimi A, Russell P, Winn H, Colvin R . Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation. 1986; 41(5):572-8. DOI: 10.1097/00007890-198605000-00004. View

Carpenter J, Cherney B, Lubinecki A, Ma S, Marszal E, Mire-Sluis A . Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation. Biologicals. 2010; 38(5):602-11. DOI: 10.1016/j.biologicals.2010.07.002. View

Richards J, Auger J, Peace D, Gale D, Michel J, KOONS A . Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. Cancer Res. 1999; 59(9):2096-101. View

Rosendaal F, Nieuwenhuis H, van den Berg H, Heijboer H, Mauser-Bunschoten E, van der Meer J . A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood. 1993; 81(8):2180-6. View

Korswagen L, Bartelds G, Krieckaert C, Turkstra F, Nurmohamed M, van Schaardenburg D . Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 2011; 63(4):877-83. DOI: 10.1002/art.30209. View

10.

van de Putte L, Atkins C, Malaise M, Sany J, Russell A, Van Riel P . Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004; 63(5):508-16. PMC: 1755008. DOI: 10.1136/ard.2003.013052. View

11.

Scandella D, DeGraaf Mahoney S, Mattingly M, ROEDER D, Timmons L, Fulcher C . Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci U S A. 1988; 85(16):6152-6. PMC: 281923. DOI: 10.1073/pnas.85.16.6152. View

12.

Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O . Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2009; 65(5):657-61. DOI: 10.1111/j.1398-9995.2009.02280.x. View

13.

Astermark J . Prevention and prediction of inhibitor risk. Haemophilia. 2012; 18 Suppl 4:38-42. DOI: 10.1111/j.1365-2516.2012.02827.x. View

14.

Chirino A, Mire-Sluis A . Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol. 2004; 22(11):1383-91. DOI: 10.1038/nbt1030. View

15.

Parker E, Healey J, Barrow R, Craddock H, Lollar P . Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood. 2004; 104(3):704-10. DOI: 10.1182/blood-2003-11-3891. View

16.

Jefferis R . Glycosylation of recombinant antibody therapeutics. Biotechnol Prog. 2005; 21(1):11-6. DOI: 10.1021/bp040016j. View

17.

Lollar P, Parker E, Curtis J, Helgerson S, HOYER L, Scott M . Inhibition of human factor VIIIa by anti-A2 subunit antibodies. J Clin Invest. 1994; 93(6):2497-504. PMC: 294465. DOI: 10.1172/JCI117259. View

18.

Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic M, Saxne T . Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006; 54(12):3782-9. DOI: 10.1002/art.22214. View

19.

Ross C, Clemmesen K, Svenson M, Sorensen P, Koch-Henriksen N, Skovgaard G . Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol. 2000; 48(5):706-12. View

20.

Christen U, Thuerkauf R, Stevens R, LESSLAUER W . Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities. Hum Immunol. 1999; 60(9):774-90. DOI: 10.1016/s0198-8859(99)00068-3. View